Clinical Trial Update: Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing efficacy and safety of GM602 in acute middle cerebral artery ischemic stroke within 18 hours has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• GM602

Snippet

Sponsor: Genervon Biopharmaceuticals, LLC | Conditions: Stroke | Phase 2 | Status: COMPLETED